Published in Am J Pathol on December 01, 1978
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol (1985) 2.87
Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun (1984) 2.86
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol (1986) 2.18
Respiratory syncytial virus infection in mice. Infect Immun (1984) 2.14
Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest (1997) 2.10
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol (1991) 2.05
Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol (1998) 1.88
Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun (1983) 1.88
Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol (1987) 1.83
Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent. Mucosal Immunol (2010) 1.78
Respiratory syncytial virus infection in inbred mice. Infect Immun (1979) 1.60
Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol (2011) 1.57
The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. J Virol (2005) 1.50
Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies. J Virol (2004) 1.49
Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. J Virol (2005) 1.42
Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother (1987) 1.40
Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci U S A (1994) 1.40
Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother (1980) 1.28
Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One (2012) 1.21
New insights for development of a safe and protective RSV vaccine. Hum Vaccin (2010) 1.18
Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants. Infect Immun (1979) 1.18
Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity. J Virol (2007) 1.18
The cotton rat model of respiratory viral infections. Biologicals (2009) 1.17
Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design. Front Immunol (2014) 1.13
Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. Infect Immun (1979) 1.13
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun (2015) 1.12
In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob Agents Chemother (1982) 1.10
The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert Rev Anti Infect Ther (2010) 1.10
Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother (1987) 1.04
Chinchilla and murine models of upper respiratory tract infections with respiratory syncytial virus. J Virol (2005) 1.03
Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats. J Gen Virol (2008) 1.03
Flow cytometric analysis of pulmonary lymphocytes from mice infected with respiratory syncytial virus. Clin Exp Immunol (1989) 1.02
Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med (1998) 1.01
Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother (2004) 1.00
Respiratory syncytial virus can tolerate an intergenic sequence of at least 160 nucleotides with little effect on transcription or replication in vitro and in vivo. J Virol (2000) 0.99
Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob Agents Chemother (2002) 0.98
RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother (2002) 0.97
Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev (1995) 0.97
New immune pathways from chronic post-viral lung disease. Ann N Y Acad Sci (2010) 0.96
Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins. J Immunol (2011) 0.96
Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother (1993) 0.96
Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats. J Virol (1990) 0.95
Development of cell-mediated cytotoxic activity in the respiratory tract after experimental infection with respiratory syncytial virus. Clin Exp Immunol (1985) 0.95
Neonatal respiratory syncytial virus infection: role of transplacentally and breast milk-acquired antibodies. J Virol (1986) 0.94
Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. Infect Immun (1982) 0.94
Alterations in pulmonary ultrastructure and morphometric parameters induced by parainfluenza (Sendai) virus in rats during postnatal growth. Am J Pathol (1984) 0.94
Wall Teichoic Acid Glycosylation Governs Staphylococcus aureus Nasal Colonization. MBio (2015) 0.93
Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol (2003) 0.93
Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics. Curr Med Chem (2012) 0.93
Viral bronchiolitis during early life induces increased numbers of bronchiolar mast cells and airway hyperresponsiveness. Am J Pathol (1990) 0.92
Rodent models of cardiopulmonary disease: their potential applicability in studies of air pollutant susceptibility. Environ Health Perspect (1998) 0.92
A nasal epithelial receptor for Staphylococcus aureus WTA governs adhesion to epithelial cells and modulates nasal colonization. PLoS Pathog (2014) 0.90
Methods for monitoring dynamics of pulmonary RSV replication by viral culture and by real-time reverse transcription-PCR in vivo: Detection of abortive viral replication. Curr Protoc Cell Biol (2010) 0.88
Bronchiolitis obliterans and pneumonia induced in young dogs by experimental adenovirus infection. Am J Pathol (1985) 0.88
Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol (2000) 0.88
Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats. Infect Immun (1982) 0.87
PROPHYLACTIC ANTIBODY TREATMENT AND INTRAMUSCULAR IMMUNIZATION REDUCE INFECTIOUS HUMAN RHINOVIRUS 16 LOAD IN THE LOWER RESPIRATORY TRACT OF CHALLENGED COTTON RATS. Trials Vaccinol (2014) 0.86
HIV type-1 infection of the cotton rat (Sigmodon fulviventer and S. hispidus). Proc Natl Acad Sci U S A (1998) 0.86
Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection. J Virol (1993) 0.84
Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model. J Interferon Cytokine Res (2010) 0.84
T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death. J Allergy Clin Immunol (2013) 0.83
A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine (2013) 0.82
Comparison of airway measurements during influenza-induced tachypnea in infant and adult cotton rats. BMC Pulm Med (2009) 0.82
Pathogenesis of bronchiolitis and pneumonia induced in neonatal and weanling rats by parainfluenza (Sendai) virus. Am J Pathol (1987) 0.82
Animal models of respiratory syncytial virus infection and disease. Curr Opin Virol (2015) 0.81
Respiratory syncytial virus replication is prolonged by a concomitant allergic response. Clin Exp Immunol (2007) 0.81
Recombinant type 5 adenoviruses expressing bovine parainfluenza virus type 3 glycoproteins protect Sigmodon hispidus cotton rats from bovine parainfluenza virus type 3 infection. J Virol (1995) 0.81
Recombinant subgroup B human respiratory syncytial virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells and is virulent in cotton rats. J Virol (2014) 0.81
Experimental pneumonia in gnotobiotic calves produced by respiratory syncytial virus. Br J Exp Pathol (1984) 0.81
Experimental models for study of common respiratory viruses. Environ Health Perspect (1980) 0.81
Inactivation of respiratory syncytial virus by zinc finger reactive compounds. Virol J (2010) 0.80
Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus). Comp Med (2015) 0.80
Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant (2015) 0.80
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob Agents Chemother (2010) 0.79
Mapping the anatomy of respiratory syncytial virus infection of the upper airways in chinchillas (Chinchilla lanigera). Comp Med (2010) 0.79
Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med (2015) 0.78
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol (2016) 0.78
Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy. Vaccine (2015) 0.77
Cell-mediated immune response to respiratory syncytial virus infection in owl monkeys. Clin Exp Immunol (1983) 0.77
Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age. J Virol (2014) 0.77
Modeling Human Respiratory Viral Infections in the Cotton Rat (Sigmodon hispidus). J Antivir Antiretrovir (2014) 0.76
Dual effects of respiratory syncytial virus infections on airway inflammation by regulation of Th17/Treg responses in ovalbumin-challenged mice. Inflammation (2014) 0.76
Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection. Antimicrob Agents Chemother (2015) 0.76
Synergistic induction of interferon α through TLR-3 and TLR-9 agonists stimulates immune responses against measles virus in neonatal cotton rats. Vaccine (2013) 0.76
Epithelial cell lines of the cotton rat (Sigmodon hispidus) are highly susceptible in vitro models to zoonotic Bunya-, Rhabdo-, and Flaviviruses. Virol J (2016) 0.75
Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus. Clin Diagn Lab Immunol (1994) 0.75
Definition of cotton rat immunoglobulins: sigmodon species differ in expression of IgG isotypes and production of respiratory syncytial virus antibody. Immunology (1996) 0.75
Passive narcosis for anesthesia induction in cotton rats (Sigmodon hispidus). Lab Anim (NY) (2016) 0.75
Animal models of respiratory syncytial virus infection. Vaccine (2016) 0.75
Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats. Hum Vaccin Immunother (2015) 0.75
Preparation of a semipermanent mounting medium for fluorescent antibody studies. Virology (1960) 7.59
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 6.85
Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol (1969) 4.97
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93
Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol (1970) 3.83
An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol (1966) 3.72
Respiratory syncytial virus. III. Production of illness and clinical observations in adult volunteers. JAMA (1961) 2.80
Plaque assay of dengue and other group B arthropod-borne viruses under methyl cellulose overlay media. Virology (1963) 2.56
Immunofluorescence assay for antigen and antibody in lactic dehydrogenase virus infection of mice. J Immunol (1969) 2.24
The pathogenesis of respiratory syncytial virus infection in infant ferrets. Am J Pathol (1976) 1.97
Cryostat microtomy of lung tissue in an expanded state. Stain Technol (1975) 1.19
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85
Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol (1972) 9.12
Enzyme-linked immunosorbent assay (ELISA) for detection of human reovirus-like agent of infantile gastroenteritis. Lancet (1977) 7.84
Human reovirus-like agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children. N Engl J Med (1976) 7.57
Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol (1992) 7.14
Genes of human (strain Wa) and bovine (strain UK) rotaviruses that code for neutralization and subgroup antigens. Virology (1981) 6.94
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 6.85
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A (1995) 6.51
A colour test for the measurement of antibody to certain mycoplasma species based upon the inhibition of acid production. J Hyg (Lond) (1966) 6.23
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A (1991) 6.13
Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med (1966) 5.97
Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity. Proc Natl Acad Sci U S A (1985) 5.94
Adsorption of Mycoplasma pneumoniae to neuraminic acid receptors of various cells and possible role in virulence. J Bacteriol (1968) 5.81
Color test for the measurement of antibody to T-strain mycoplasmas. J Bacteriol (1966) 5.61
Reoviruslike agent in stools: association with infantile diarrhea and development of serologic tests. Science (1974) 5.32
Human rotavirus type 2: cultivation in vitro. Science (1980) 5.22
Definition of human rotavirus serotypes by plaque reduction assay. Infect Immun (1982) 5.19
Epidemiology of human rotavirus Types 1 and 2 as studied by enzyme-linked immunosorbent assay. N Engl J Med (1978) 4.73
Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol (1973) 4.47
Rescue of noncultivatable human rotavirus by gene reassortment during mixed infection with ts mutants of a cultivatable bovine rotavirus. Proc Natl Acad Sci U S A (1981) 4.47
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Comparison of human and animal rotavirus strains by gel electrophoresis of viral RNA. Virology (1978) 4.08
Solid-phase microtiter radioimmunoassay for detection of the Norwalk strain of acute nonbacterial, epidemic gastroenteritis virus and its antibodies. J Med Virol (1978) 4.06
Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis (1973) 3.89
Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. J Infect Dis (1971) 3.88
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Cloning full-length dengue type 4 viral DNA sequences: analysis of genes coding for structural proteins. Virology (1986) 3.85
Antigenic characterization of human and animal rotaviruses by immune adherence hemagglutination assay (IAHA): evidence for distinctness of IAHA and neutralization antigens. Infect Immun (1981) 3.83
Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol (1973) 3.77
An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol (1966) 3.72
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology (1998) 3.60
New complement-fixation test for the human reovirus-like agent of infantile gastroenteritis. Nebraska calf diarrhea virus used as antigen. Lancet (1975) 3.56
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med (1972) 3.51
Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A (1967) 3.47
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol (1969) 3.39
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
Growth of Mycoplasma pneumoniae on a glass surface. Ann N Y Acad Sci (1967) 3.31
Use of transcription probes for genotyping rotavirus reassortants. Virology (1982) 3.23
Comparison of the amino acid sequences of the major neutralization protein of four human rotavirus serotypes. Virology (1987) 3.22
Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun (1982) 3.22
A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A (1991) 3.21
Sequence of the fourth gene of human rotaviruses recovered from asymptomatic or symptomatic infections. J Virol (1988) 3.20
Distinctive ribonucleic acid patterns of human rotavirus subgroups 1 and 2. Infect Immun (1981) 3.13
Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis (1974) 3.10
Comparison of direct electron microscopy, immune electron microscopy, and rotavirus enzyme-linked immunosorbent assay for detection of gastroenteritis viruses in children. J Clin Microbiol (1981) 3.05
Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol (1985) 2.95
Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteritis. Proc Soc Exp Biol Med (1972) 2.94
Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4. Proc Natl Acad Sci U S A (1990) 2.90
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol (1985) 2.87
A color test for the measurement of antibody to the non-acid-forming human Mycoplasma species. Am J Epidemiol (1966) 2.81
Antigenic relationships among five reovirus-like (RVL) agents by complement fixation (CF) and development of new substitute CF antigens for the human RVL agent of infantile gastroenteritis. Proc Soc Exp Biol Med (1976) 2.74
Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci U S A (1989) 2.74
Pattern of shedding of the Norwalk particle in stools during experimentally induced gastroenteritis in volunteers as determined by immune electron microscopy. J Infect Dis (1975) 2.74
Microtiter solid-phase radioimmunoassay for detection of Escherichia coli heat-labile enterotoxin. Infect Immun (1977) 2.72
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Immunological response to infection with human reovirus-like agent: measurement of anti-human reovirus-like agent immunoglobulin G and M levels by the method of enzyme-linked immunosorbent assay. Infect Immun (1978) 2.64
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Mapping of the two overlapping genes for polypeptides NS1 and NS2 on RNA segment 8 of influenza virus genome. Proc Natl Acad Sci U S A (1980) 2.60
Proteins of Norwalk virus. J Virol (1981) 2.59
A complement-fixation test for measuring Australia antigen and antibody. J Infect Dis (1969) 2.58
Comparative epidemiology of two rotavirus serotypes and other viral agents associated with pediatric gastroenteritis. Am J Epidemiol (1979) 2.56
Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol (1983) 2.50
Biophysical properties of Australia antigen. J Virol (1969) 2.45
Oncogenic association of specific human papillomavirus types with cervical neoplasia. J Natl Cancer Inst (1987) 2.45
Immunologic relatedness of papillomaviruses from different species. J Natl Cancer Inst (1980) 2.44
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
Prediction of human rotavirus serotype by nucleotide sequence analysis of the VP7 protein gene. J Virol (1988) 2.44
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol (1997) 2.43
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Conservation of the fourth gene among rotaviruses recovered from asymptomatic newborn infants and its possible role in attenuation. J Virol (1986) 2.42
Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res (1985) 2.42
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Differentiation of human and calf reoviruslike agents associated with diarrhea using polyacrylamide gel electrophoresis of RNA. Virology (1976) 2.40
Approaches to immunization of infants and young children against gastroenteritis due to rotaviruses. Rev Infect Dis (1980) 2.39
Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus. J Virol (1988) 2.38
Conservation of amino acid sequence of VP8 and cleavage region of 84-kDa outer capsid protein among rotaviruses recovered from asymptomatic neonatal infection. Proc Natl Acad Sci U S A (1986) 2.37